Protai, a start-up for the discovery and development of drugs based on artificial intelligence, raised $ 8 million in a lime round, led by the Grove Foundation and the Pitango Foundation. The funding will be used to expand the company’s platform development, accelerate independent drug development and expand its partnerships with drug companies.
Protei is developing an artificial intelligence-based platform that allows accurate mapping of the course of the disease at the protein level in different activity states and thus expands the ability to observe cell function and improve the way new drugs can be detected and developed. The company states that this comprehensive approach allows the company to increase the level of accuracy in drug detection, optimize development processes and save time and costs.
Eran Zeger, CEO and co-founder of Protai: “Protai is like an advanced GPS to guide the drug discovery process, we systematically map the activity of proteins and thus create an innovative layer of functional information that allows us to understand how to target and fight more effectively and accurately in a wide range of complex diseases.”
The company estimates that understanding the molecular mechanisms of complex diseases such as cancer, autoimmune diseases and neurodegenerative diseases, is one of the major challenges in the process of drug discovery and development. Limited information about these mechanisms is the main reason for the failure of over 99% of drugs in the various stages of development. Existing technology today, which is largely based on mapping the genomic profile of the disease, produces a partial snapshot that does not provide the depth required to understand the biological complexity of various disease states.
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment
.